Your browser doesn't support javascript.
loading
Systemic therapy of atopic dermatitis.
Bußmann, C; Novak, N.
Afiliación
  • Bußmann C; Klinik und Poliklinik für Dermatologie und Allergologie, Universität Bonn, Germany.
  • Novak N; N. Novak is being supported by a DFG NO454/5-2 Heisenberg professorship.
Allergol Select ; 1(1): 1-8, 2017.
Article en En | MEDLINE | ID: mdl-30402595
Therapy of severe atopic dermatitis, which is refractory to consistent treatment with topical steroids and topical calcineurin inhibitors is still a problem in many cases. The use of cyclosporine, which is the only approved systemic drug for the therapy of severe atopic dermatitis, is often limited by contraindications or adverse reactions. In this context, results from controlled and open-label studies with novel therapeutic approaches such as methotrexate, omalizumab or rituximab, which are in part very promising, are of great interest. In this work we would like to provide an overview of established and new therapeutic options for the treatment of severe atopic dermatitis.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Allergol Select Año: 2017 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Allergol Select Año: 2017 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Alemania